© Copyright 2024 Synerphysics, Inc. All rights reserved. Dillon Capital Strategies is an operating unit of SynerPhysics, Inc.
Joseph S. Dillon, PH.D., MBA
President, Dillon Capital Strategies
Joseph S. Dillon, Ph.D., MBA, is President & CEO of
SynerPhysics, Inc. and President of Dillon Capital
Strategies, the strategy and business analytics advisory
arm of SynerPhysics. Dr. Dillon is a seasoned
pharmaceutical executive with over 30 years of
experience. He has extensive experience in global
pharmaceutical business development, planning and
analysis, corporate finance, M&A, licensing, and
technology valuations. Dr. Dillon has screened
thousands of opportunities, valued over 400 deals and
has been in a lead role for over 45 closed transactions
over the course of his career. Since forming Dillon Capital Strategies, Dr. Dillon has
consulted dozens of companies and held interim senior positions, including CEO, CFO,
and Head of BD at select clients. Dr. Dillon also provides specialized, strategic and
transaction focused training for biopharma professionals. Prior to this, Dr. Dillon held
senior positions in pharmaceutical management consulting firms, most significantly as
Senior Vice President, Head of Corporate Development Services and Valuations for The
Mattson Jack Group (now Cerner). Other previous positions include CEO, President, and
Director of The Pharmaceutical Development Center (sold to AAI), a pharmaceutical
developer and manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-
bank holding company (IPO, then sold to US Bancorp); CFO and Treasurer of Oread Inc., a
contract pharmaceutical developer and manufacturer; and corporate positions with
predecessor companies of Sanofi. Dr. Dillon is Past-Chairperson of the Licensing
Executive Society Life Sciences Sector. He is a veteran speaker at BIO, LES, WBR, EBD, and
other prominent industry organization events. Dr. Dillon holds a Ph.D. in Theoretical
Physics, an M.B.A. in International Finance, and a bachelor’s degree in Finance.